Abstract: The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by solution/suspension layering, optionally coated with a delayed release coating; the solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.

Abstract: The present invention includes compositions and methods for treating a proliferative disorder comprising administering a therapeutically effective amount of an liposomal curcumin or curcuminoids to a human subject in need thereof in accordance with a dosing regimen comprising: at least one treatment cycle administering the therapeutically effective amount of the liposomal curcumin or curcuminoids once per week of at least 100 mg/m2 over 8 hours.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.

Abstract: The invention is based on the discovery that rho kinase inhibitors can be used to treat proteinopathy associated wandering. A number of degenerative neurological diseases are thought to be caused, at least in part, by the formation of protein aggregates that cause neurotoxicity and progressive decline in function. The inventive methods related to the use of rho kinase inhibitors in the treatment of patients with proteinopathy-associated wandering. The patients may be suffering from Huntington's disease, a traumatic brain injury, autism spectrum disorder, Down syndrome or a proteinopathy-associated dementia, such as Alzheimer disease or frontotemporal dementia.

Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.

Abstract: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

Abstract: Provided herein are branched poly(beta-amino esters) (PBAE) useful as vehicles for the delivery of therapeutic agents, such as nucleic acids. The disclosed polymers form stable compositions, and are suitable for the delivery of therapeutic agents via nebulization. Compositions of the disclosed polymers are capable of delivering therapeutic agents such as mRNA to lung epithelial cells.

Abstract: A pharmaceutical composition having consistently a desirable release rate is prepared by controlling the finally mixing time based on the molecular weight measured in the intermediate product. The pharmaceutical composition includes micro particles containing a polyhydric alcohol, a salt, a water-soluble polymer and a pharmaceutically active ingredient. The micro particles are dispersed in a matrix of a hydrophobic ingredient and an amphipathic ingredient.

Abstract: A gummy composition including: 10 to 45 percent by weight of the composition of a protein, wherein a portion of the protein is hydrolyzed; Maltitol syrup; sugar; a structurant; and Water. A method of manufacture of a gummy composition including: Forming a mixture comprising 10 to 45 percent by weight of the composition of a protein, maltitol syrup, sugar, a structurant and water, wherein a portion of the protein is hydrolyzed; and cooking the mixture at a temperature of 85° C. or less.

Abstract: Gellan gum-based hydrogels are disclosed herein for in vitro cell culture and tissue engineering and regenerative medicine applications. Such gellan gum-based hydrogels may be used alone or combined with live cells and/or biomolecules for application in humans and/or animals. Chemical modification of gellan gum with selected ion-chelating substituents affords novel gellan gum hydrogels endowed with tunable physicochemical and biological properties. The modified gellan gum hydrogels described herein present advantages over existing hydrogel systems, including solubility, ionic crosslinking versatility, ease of formulation and injectability and greater adhesiveness within biological tissues and surfaces, whilst maintaining encapsulated cells viable during long culture periods and up-regulating the expression of healthy extracellular matrix markers.

Abstract: Provided are an absorbable biomedical composite material and a preparation method therefor. The absorbable biomedical composite material comprises: substrate granules containing a calcium-phosphorus compound; an intermediate layer which is coated on the surface of each of the substrate granules and has a first glass transition temperature, the first glass transition temperature being not higher than normal human body temperature; and a polymer matrix which is formed on the outer surface of the intermediate layer and has a second glass transition temperature, the second glass transition being higher than the first glass transition temperature. The absorbable biomedical composite material has increased mechanical strength and also improved toughness.

Abstract: The invention relates to novel antimicrobial surfactants and their application in antimicrobial coating systems, in particular water borne coatings. Provided is a method for providing an antimicrobial surfactant, comprising the steps of: (a) providing a hyperbranched polyurea having blocked isocyanates at the end of the polymer branches by the polycondensation of AB2 monomers; (b) introducing tertiary amine groups by reacting said blocked isocyanates of the hyperbranched polyurea with a tertiary amine compound that is functionalized with —OH, —NH2, —SH, or —COO—; and (c) quaternization of said tertiary amine groups by reacting with an alkylating agent to obtain a quaternized hyperbranched polymer having antimicrobial surfactant properties.

Abstract: The disclosure provides a drug delivery device that can release a drug or other molecule of interest in response to application of a mechanical force, such as tension, and methods of use thereof. The present disclosure provides a tension-responsive drug delivery device by exploiting a difference in mechanical properties between a drug-loaded core material and a supertiydrophobic barrier coating consisting of interconnected micro- and nano-sized particles formulated via the electrospraying of a mixture of biocompatible polymers.

Abstract: Fill stations and base stations are provided for personal pump systems. The fill stations may be opened and closed to accept a reservoir and to allow fluid to be introduced into the reservoir for use with personal pump systems. The fill stations may hold the reservoir at a tilt relative to an underlying surface and may discourage overfilling of the reservoir. The filling stations may also include viewing windows having fluid lines marked thereon for indicating volume of fluid within the reservoir.

Abstract: Capsules with a cement additive covered by a polymeric outer shell are added to wellbore cement. The additive is released from the shells by osmosis or shell ruptures. Capillary forces draw the additive into micro-annuli or cracks present in the cement, where the additive seals the micro-annuli and cracks to define a self-sealing material. The empty shells remain in the cement and act as an additive that modifies cement elasticity. The capsules are formed by combining immiscible liquids, where one of the liquids contains a signaling substance, and each of the liquids contains a reagent. When combined, the liquids segregate into a dispersed phase and a continuous phase, with the dispersed phase having the signaling agent. The reagents react at interfaces between dispersed and continuous phases and form polymer layers encapsulating the signaling agent to form the capsules. Adjusting relative concentrations of the reagents varies membrane strength and permeability.

Abstract: Porous metal oxide microspheres are prepared via a process comprising forming a liquid solution or dispersion of polydisperse polymer nanoparticles and a metal oxide; forming liquid droplets from the solution or dispersion; drying the liquid droplets to provide polymer template microspheres comprising polymer nanospheres and metal oxide; and removing the polymer nanospheres from the template microspheres to provide the porous metal oxide microspheres. The porous microspheres exhibit saturated colors and are suitable as colorants for a variety of end-uses.

Abstract: Porous metal oxide microspheres are prepared via a process comprising forming a liquid dispersion of polymer nanoparticles and a metal oxide; forming liquid droplets of the dispersion; drying the droplets to provide polymer template microspheres comprising polymer nanospheres; and removing the polymer nanospheres from the template microspheres to provide the porous metal oxide microspheres. The porous microspheres exhibit saturated colors and are suitable as colorants for a variety of end-uses.

Abstract: The present invention has publicized a bacteria culture medium. In common bacteria culture medium, one kind or several kinds of ?-lactam antibiotics and/or the salts thereof were premixed. The ?-lactam antibiotics and/or the salts thereof premixed in the bacteria culture medium is slightly soluble in water at 25° C. and the solubility is less than 10 mg/ml. The concentrations of the ?-lactam antibiotics premixed in the culture medium are greater than the solubility of the used ?-lactam antibiotics at 25° C., but are less than 100 mg/ml. The bacteria culture medium can be used to selectively culture bacteria with ?-lactam antibiotic resistance and can be stored for a long time.

Abstract: Disclosed is a system and method of treatment which provides a direct response to the treatment of pneumonia as related to infections using a powder comprising a polyiodide resin with broad spectrum bactericidal, fungicidal and virucidal properties. When the powder is applied directly to the lungs of a mammal an immediate contact kill of protozoa, bacteria, fungi and viruses that cause respiratory tract infections affecting the lungs of a mammal takes place. Also disclosed is an application of the polyiodide resin powder for use with personal protective equipment (PPE) including but not limited to face masks, face shields, and respirators.

Abstract: It is an object of the present invention to provide a pattern forming method capable of easily forming a phase-separated structure with high accuracy, even in the case of widening the applicable range of a pattern size. The present invention relates to a pattern forming method comprising: applying an under coating agent onto a substrate, and applying a self-assembly composition for pattern formation to the surface of the substrate, onto which the under coating agent has been applied, and then forming a self-assembly film according to self-assembly phase separation, wherein the self-assembly composition for pattern formation comprises a block copolymer comprising a polymerization unit (a) having at least one selected from a structure represented by a formula (103) and a structure represented by a formula (104), and a polymerization unit (b) having a structure represented by a formula (105).

Abstract: A method for forming a photosensitizer product that is resistant to absorption by living tissue that may include binding a photosensitizer compound with an oxide-containing particle to provide the photosensitizer derivative having a microscale size, and mixing the photosensitizer derivative into a lotion. The microscale size of the photosensitizer derivative obstructs absorption by cell tissue.

Abstract: Provided herein are improved compositions and methods of making and using the same, the composition comprising a polymer and a ceramic present at a ratio of from 3:1 to 1:3 of polymer:ceramic by weight, wherein the composition comprises or is a composite of the polymer and the ceramic having improved printability and/or having an improved elastic modulus and/or improved stress at failure (e.g., as compared to a blend of the polymer and the ceramic).

Abstract: A membrane for filtering one or more hydrophobic organic contaminants can include a porous nanostructure that includes one or more of a metal, a metal oxide, and a metal alloy nanostructure component functionalized with one or more amphiphilic ligands.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: A delayed release drug formulation includes a core and a coating. The coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release drug formulation is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: Embodiments of the invention are related generally to compositions comprising Co-Q10, a source of omega-3 fatty acids, and vitamin D, and methods of making thereof. In particular, the invention relates to stable compositions comprising Co-Q10, krill oil, vitamin D, and an antioxidant suitable for use as dietary supplements, and methods of making thereof. The compositions may further comprise an emulsifier to impart stability to the compositions.

Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

Abstract: A delayed release coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release coating is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: Disclosed is a system and method of treatment which provides a direct response to the treatment of pneumonia as related to infections using a powder comprising a polyiodide resin with broad spectrum bactericidal, fungicidal and virucidal properties. When the powder is applied directly to the lungs of a mammal an immediate contact kill of protozoa, bacteria, fungi and viruses that cause respiratory tract infections affecting the lungs of a mammal takes place.

Abstract: Methods and apparatus for processing fluids on a macro- or micro-scale are described. In various aspects, a fluid may have a plurality of elongated (i.e., substantially rod-shaped) magnetic elements disposed therein within a fluid container. An illustrative fluid container is an actuator electrode or a processing vial of a microfluidic device, such as a digital microfluidic device. A magnet component may be configured to generate a magnetic force sufficient to influence the movement of the plurality of elongated magnetic elements within the fluid to be processed. For example, the magnetic force (or magnetic force gradient) may influence the plurality of elongated magnetic elements to rotate, spin, and/or move laterally side-to-side. The shape and movements of the plurality of elongated magnetic elements facilitate the rapid and efficient processing of the fluid, such as fluid mixing and/or fluid separation.

Abstract: A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 ?m to 20 ?m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.

Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.

Abstract: The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.

Abstract: In one aspect, methods of targeted nanoparticle and cell delivery are described herein. In some embodiments, methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.

Abstract: Provided herein are amphiphilic polymers compositions for making aqueous formulations. In one aspect, a solution composition for delivery and release of active ingredients comprises a block co-polymer having formula: PEG-PCL-PLA-PCL-PEG or PGA-PCL-PEG-PCL-PGA or PLA-PCL-PEG-PCL-PLA or PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG-PGA-PCL. The block co-polymers are biodegradable, stable and compatible with hydrophilic, hydrophobic, and combinations thereof, biologic or chemical active agents. In some embodiments, the block co-polymers enable sustained and/or continuous release of various active agents. In certain embodiments, the block co-polymers can be used to make an artificial tear preparation, a lubricant for joints or wound cover or adhesive.

Abstract: Multiple emulsions and techniques for the formation of multiple emulsions are generally described. A multiple emulsion, as used herein, describes larger droplets that contain one or more smaller droplets therein. In some embodiments, the larger droplet or droplets may be suspended in a carrying fluid containing the larger droplets that, in turn, contain the smaller droplets. As described below, multiple emulsions can be formed in one step in certain embodiments, with generally precise repeatability, and can be tailored in some embodiments to include a relatively thin layer of fluid separating two other fluids.

Abstract: An abuse deterrent drug product is provided wherein the drug product comprises a matrix and a drug substance in the matrix wherein the drug substance is defined as a 1:1 salt of a pharmaceutically active compound and BNDO.

Abstract: The presently-disclosed subject matter includes nanoparticles that comprise a plurality of assembled polymers. In some embodiments the polymers comprise a first block that includes hydrophilic monomers, the first block substantially forming an outer shell of the nanoparticle, and a second block that includes cationic monomers and hydrophobic monomers, the second block substantially forming a core of the nanoparticle. In some embodiments a polynucleotide is provided that is bound to the cationic monomers of the nanoparticle. The presently-disclosed subject matter also comprises methods for using the present nanoparticles to include RNAi in a cell as well as methods for making the present nanoparticles.

Abstract: The present invention is directed to an injection syringe comprising an injectable composition, the composition comprising a penicillin, salt or prodrug thereof, one or more pharmaceutically acceptable excipients, and water, wherein the composition is free of a preservative agent. In other aspects, the invention relates to a process for producing the injection syringe, and a kit comprising the injection syringe.

Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Abstract: Effective Photodynamic therapy (PDT) against C. difficile is provided using a composition including chitosan and tetracycline.

Abstract: A nucleic acid-encapsulating polymer micelle complex is formed of a block copolymer containing an uncharged hydrophilic polymer chain block and a cationic polymer chain block; and two single-stranded DNA molecules having mutually complementary base sequences of 1000 or more bases in length, double-stranded DNA of 1000 or more base pairs in length in which at least a part of a double helix structure is dissociated and forms a single-stranded structure, or one single-stranded DNA molecule of 1000 or more bases in length.